Quantcast

Industry news that matters to you.  Learn more

Archives for January 2011

Veridex to Develop Next-Generation Circulating Tumor Cell Technology with MGH

Earlier this month, Veridex announced a collaboration with Massachusetts General Hospital (MGH) to develop and commercialize a next-generation circulating tumor cell (CTC) technology for capturing, counting and characterizing tumor cells found in patients’ blood. The platform to be developed will be a bench-top system to specifically isolate and explore the biology of rare cells at the protein, RNA and DNA levels.

Beckman Coulter to Develop a TG4010 Companion Diagnostic Test for Transgene

Transgene has announced that they have signed an agreement with Beckman Coulter, under which Beckman Coulter will develop a companion test that measures the level of activated natural killer cells for Transgene in order to select patients that can be treated with TG4010.

BG Medicine and Siemens Healthcare to Develop Galectin-3 Test

BG Medicine has entered into a development agreement with Siemens Healthcare diagnostics division for a heart-failure test based on its recently FDA-cleared Galectin-3 test. The agreement allows for the development and commercialization of a Galectin-3 test for Siemens’ automated immunoassay platforms for clinical laboratories.

GenomeQuest and Ingenuity Systems Partner to Support NGS Workflows for Personalized Medicine

Earlier this month, GenomeQuest and Ingenuity Systems announced a partnership to support next-generation sequencing workflows specifically targeted for personalized medicine research. The partnership integrates GenomeQuest’s Sequence Data Management (SDM) platform with Ingenuity’s IPA software, enabling researchers to seamlessly exchange gene information, perform interactive analysis, and create and test hypotheses across the domains of genome sequencing and biological pathways.

Nuclea Biotechnologies and Boston Medical Center Announce Unique Partnership

Biomarker pioneer Nuclea Biotechnologies, Inc. today announced a new partnership with Boston Medical Center (BMC) that could lead to more effective treatments for people with breast and prostate cancers. The pairing of the Pittsfield and Worcester-based biotech firm and one of Boston’s leading teaching hospitals will significantly advance research and development of biomarkers, a key component in the growing field of personalized medicine.